When to use SODERMIX®
Skin psoriasis is a very prevalent disease, and it's particularly prevalent in Northern Europe and Scandinavia: there have been some recent studies in Norway where population prevalence exceeding 4% has been suggested.
The vast majority of patients have disease onset before the age of 40 years.
In patients with skin psoriasis, the quality of life is comparable to severe conditions, such as cancer, heart attack, arthritis and diabetes mellitus, as well with regard to the physical component as to the mental scores.
In psoriasis, there is a central role for the interaction between T cells and activated macrophages.
Both CD4 + T cells and CD8+ positive cells ultimately lead to activation of macrophages, and release of a variety of type 1 cytokines (Th1), such as IFN-gamma, IL-2 and TNF-alpha.
These cytokines are responsible for keratinocyte proliferation and lack of maturation, and vascular changes characteristic of psoriasis.
Then , psoriasis appears as being a typically inflammatory dermatological disorder, in which the cascade of cytokines and chemokines is particularly active .
Hence, by reducing the synthesis and secretion of cytokines and chemokines, Superoxide Dismutase (SOD) contained in SODERMIX® permits to: